{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:45:17Z","timestamp":1784241917460,"version":"3.55.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.4158\/ep10036.or","type":"journal-article","created":{"date-parts":[[2010,5,3]],"date-time":"2010-05-03T21:30:11Z","timestamp":1272922211000},"page":"934-939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Thyroid Function Outcomes after Pegylated Interferon-\u03b1 and Ribavirin Therapy - For Chronic Hepatitis C"],"prefix":"10.1016","volume":"16","author":[{"given":"Huy A.","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn E.M.","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Ianna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Leembruggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP10036.OR_bb0010","unstructured":"World Health Organization. Hepatitis C. Factsheet No. 164, revised October 2000. http:\/\/apps.who.int\/inf-fs\/en\/fact164.html"},{"key":"10.4158\/EP10036.OR_bb0015","doi-asserted-by":"crossref","first-page":"6","DOI":"10.33321\/cdi.2004.28.2","article-title":"Australia's notifiable diseases status, 2002: annual report of the National Notifiable Diseases Surveillance System","volume":"28","author":"Yohannes","year":"2004","journal-title":"Commun Dis Intell"},{"key":"10.4158\/EP10036.OR_bb0020","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.4158\/EP10036.OR_bb0025","doi-asserted-by":"crossref","first-page":"770","DOI":"10.7326\/0003-4819-144-10-200605160-00011","article-title":"Hepatitis C: a bitter harvest","volume":"144","author":"Dienstag","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.4158\/EP10036.OR_bb0030","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1136\/bmj.332.7548.1013","article-title":"Diagnosis and treatment of chronic hepatitis C infection","volume":"332","author":"Patel","year":"2006","journal-title":"BMJ"},{"key":"10.4158\/EP10036.OR_bb0035","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2893.2005.00563.x","article-title":"Therapeutic modalities in hepatitis C: challenges and development","volume":"12","author":"Moreno-Otero","year":"2005","journal-title":"J Viral Hepat"},{"key":"10.4158\/EP10036.OR_bb0040","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1210\/jc.2004-0627","article-title":"Clinical review 169: interferon-alpha-related thyroid disease; pathophysiological, epidemiological, and clinical aspects","volume":"89","author":"Carella","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP10036.OR_bb0045","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/TEN.0b013e3180dc91d3","article-title":"Hepatitis C infection, treatment regimens, and thyroid function abnormalities","volume":"17","author":"Tran","year":"2007","journal-title":"Endocrinologist"},{"key":"10.4158\/EP10036.OR_bb0050","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1089\/105072503322238809","article-title":"Interferon-alpha and autoimmune thyroid disease","volume":"13","author":"Prummel","year":"2003","journal-title":"Thyroid"},{"key":"10.4158\/EP10036.OR_bb0055","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1586\/egh.09.60","article-title":"Optimizing the treatment of chronic viral hepatitis C","volume":"3","author":"Fran\u00e7ois","year":"2009","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.4158\/EP10036.OR_bb0060","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1472-6823-5-8","article-title":"The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with combination interferon-alpha2beta and ribavirin","volume":"5","author":"Tran","year":"2005","journal-title":"BMC Endocr Disord"},{"key":"10.4158\/EP10036.OR_bb0065","first-page":"1925","article-title":"Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment","volume":"86","author":"Carella","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP10036.OR_bb0070","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1478-3231.2005.01089.x","article-title":"Long-term outcome of interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C","volume":"25","author":"Doi","year":"2005","journal-title":"Liver Int"},{"key":"10.4158\/EP10036.OR_bb0075","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1590-8658(01)80715-5","article-title":"Interferonrelated thyroid autoimmunity and long-term clinical outcome of chronic hepatitis C","volume":"33","author":"Morisco","year":"2001","journal-title":"Dig Liver Dis"},{"key":"10.4158\/EP10036.OR_bb0080","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.510260330","article-title":"Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial","volume":"26","author":"Tong","year":"1997","journal-title":"Hepatology"},{"key":"10.4158\/EP10036.OR_bb0085","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/j.1440-1746.2009.05812.x","article-title":"Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related?","volume":"24","author":"Vezali","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"10.4158\/EP10036.OR_bb0090","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3748\/wjg.v9.i7.1487","article-title":"Gastric autoimmune disorders in patients with chronic hepatitis C before, during and after interferon-alpha therapy","volume":"9","author":"Fabbri","year":"2003","journal-title":"World J Gastroenterol"},{"key":"10.4158\/EP10036.OR_bb0095","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2337\/diacare.23.8.1177","article-title":"Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection","volume":"23","author":"Betterle","year":"2000","journal-title":"Diabetes Care"},{"key":"10.4158\/EP10036.OR_bb0100","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1046\/j.1365-2265.1999.00616.x","article-title":"Recombinant interferon alpha (rIFN-alpha) does not potentiate the effect of iodine excess on the development of thyroid abnormalities in patients with HCV chronic active hepatitis","volume":"50","author":"Minelli","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP10036.OR_bb0105","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1440-1746.2009.05853.x","article-title":"Interferon-induced thyroid dysfunction\u2014not always transient","volume":"24","author":"Wong","year":"2009","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20415812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20415812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/K52H715541332128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:50:51Z","timestamp":1761515451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20415812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S1530891X20415812"],"URL":"https:\/\/doi.org\/10.4158\/ep10036.or","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thyroid Function Outcomes after Pegylated Interferon-\u03b1 and Ribavirin Therapy - For Chronic Hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP10036.OR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}